Tag Archives: Drug

Puma Biotech’s new cancer drug Nerlynx suffered a terrible quarter. What gives?

Puma Biotech has only retained commercial rights to its cancer drug Nerlynx in the U.S. and Japan after a series of licensing deals. But even the remaining U.S. launch doesn’t seem to be going well.   In the first quarter, Nerlynx ginned up sales of $ 45.6 million, Puma said Thursday. That’s way below analyst expectations of… Read More »